CMCesare Mariotti

Cesare Mariotti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cesare Mariotti has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Volume of Opercular and Pseudopercular Tissue Is Associated With Outer Retinal Reconstitution After Full-Thickness Macular Hole Surgery

    by Alberto Quarta, Ruggero Tartaro, Maria Ludovica Ruggeri, Corina De Santis Ciacci, Alessandro Avitabile, Giulia Gregori, Cesare Mariotti, Marco Lupidi, Rodolfo Mastropasqua

    Purpose: To quantitatively evaluate the operculum-pseudoperculum volume (OPV) in full-thickness macular holes (MHs) and explore its relationship with anatomical and functional outcomes following surgery. Methods: This prospective study included patients with Stage 2 and Stage 3 MHs who underwent pars plana vitrectomy. OPV was measured using image processing software and its correlation with postoperative changes in visual acuity (VA), external limiting membrane (ELM), and ellipsoid zone (EZ) defect in each group, then a median split was applied to investigate the impact of OPV on baseline and final measures. Multivariable regression analysis was conducted to determine predictors of VA improvement. Results: In stage 2 MHs, OPV positively correlated with VA, minimum diameter (MD), basal diameter (BD), MH height (MHe) and changes in ELM at 3 and 6 months (p < 0.05). Only EZ changes at 6 months negatively correlated with OPV (p < 0.05). Patients with low OPV demonstrated greater EZ and ELM defect reduction at 6 months, whereas greater ΔVA was observed in the high-OPV group (p = 0.032). Multivariate analysis revealed that MD and OPV group were independent predictors of ΔVA at six months (Adjusted R 2 = 0.266). Conclusions: OPV may represent a promising exploratory OCT-derived biomarker associated with postoperative structural and functional recovery in FTMH surgery. Larger longitudinal studies with external validation are warranted to confirm its prognostic utility.

  • Open Access

    Functional and Structural Outcomes of Photodynamic Therapy (PDT) With or Without Eplerenone for Central Serous Chorioretinopathy

    by Giulia Gregori, Chiara Centini, Lorenzo Mangoni, Alessio Muzi, Daniela Fruttini, Alberto Quarta, Maria Ludovica Ruggeri, Clara Rizzo, Giacomo Bongiovanni, Rodolfo Mastropasqua, et al.

    Background/Objectives: To evaluate whether the combination of oral eplerenone and half-dose full-fluence photodynamic therapy (HD-FF PDT) provides greater efficacy than HD-FF PDT alone in persistent central serous chorioretinopathy (CSCR). Methods: This monocentric, retrospective, observational study included patients with persistent (>6 months) simple or complex CSCR who had previously undergone either half-dose full-fluence photodynamic therapy (HD-FF PDT) alone or HD-FF PDT combined with oral eplerenone as part of routine clinical practice between September 2024 and March 2025. Functional and morphological data collected at baseline and at 1, 3, and 6 months after treatment were retrospectively reviewed. An artificial intelligence–based algorithm was used to analyze OCT scans, quantifying subretinal and intraretinal fluid volumes (SRFV, IRFV) and assessing ellipsoid zone and external limiting membrane integrity, hyperreflective foci, subfoveal choroidal thickness (SCT), and central macular thickness (CMT). Results: Fifty patients (53 eyes; mean age 52 years) were included, with no significant baseline differences between groups. Best-corrected visual acuity improved more significantly in Group B at 1 and 6 months (p = 0.032 and p = 0.009, respectively). At 6 months, subretinal fluid volume (SRFV), quantified by AI-based OCT analysis, was significantly lower in the combined therapy group (p = 0.014). An AI-defined complete resolution of subretinal fluid (SRFV < 0.010 mm3) was achieved more frequently in Group B than in Group A (77% vs. 22%, p = 0.001). Conclusions: Although HD-FF PDT remains the standard treatment for persistent CSCR, adjunctive therapy with the mineralocorticoid receptor antagonist eplerenone may enhance subretinal fluid reabsorption and improve mid-term anatomical and functional outcomes.

  • Open Access

    Anatomical and Systemic Predictors of Early Response to Subthreshold Micropulse Laser in Diabetic Macular Edema: A Retrospective Cohort Study

    by Oscar Matteo Gagliardi, Giulia Gregori, Alessio Muzi, Lorenzo Mangoni, Veronica Mogetta, Jay Chhablani, Gregorio Pompucci, Clara Rizzo, Danilo Iannetta, Cesare Mariotti, et al.

    Background/Objectives: The aim of this study was to identify anatomical and systemic predictors of early (≤2 months) response to subthreshold micropulse laser (SMPL) in center-involving diabetic macular edema (DME) using automated AI-based OCT biomarker quantification. Methods: Retrospective observational study of 65 eyes. Spectral-domain optical coherence tomography (SD-OCT) volumes were analyzed with a CE-marked software (Ophthal v1.0; Mr. Doc s.r.l., Rome, Italy) to quantify intraretinal fluid (IRF) and subretinal fluid (SRF) volumes and outer retinal integrity (external limiting membrane, ELM; ellipsoid zone, EZ). SMPL (577 nm; 5% duty cycle; 200 ms; 150 µm; 250 mW) was applied in a high-density macular grid, sparing the foveal avascular zone. The primary endpoint was absolute and percentage change in IRF volume from baseline to follow-up; predictors of %IRF reduction were assessed by multivariable linear regression. Results: At 52 days (IQR 41–60), best-corrected visual acuity improved from 0.22 to 0.15 logMAR (p < 0.001). IRF volume decreased (median −0.045 mm3; p = 0.034) despite stable central subfield thickness. All eyes with baseline SRF (n = 5; median 0.026 mm3 [0.020–0.046]) achieved complete SRF resolution. Treatment-naïve eyes had greater %IRF reduction than pretreated eyes (59.6% vs. 11.5%; p = 0.029). High responders showed shorter diabetes duration than low responders (14.5 vs. 17 years; p = 0.025); however, treatment-naïve status was the strongest independent predictor of %IRF reduction (p = 0.028). Conclusions: AI-derived fluid volumetrics capture early SMPL response despite unchanged thickness. Treatment-naïve status and shorter diabetes duration may define a metabolic window for optimal early response in DME.

  • Open Access

    Optical Coherence Tomography Study of Choroidal Response to Exercise-Induced Hypertension in Chronic Central Serous Chorioretinopathy

    by Anindya Samanta, Giulia Gregori, Alessio Muzi, Ramkailash Gujar, Cesare Mariotti, Daniela Fruttini, Kiran K. Vupparaboina, Jay Chhablani, Massimo Nicolò, Chiara M. Eandi, et al.

    Background/Objectives: The aim of this study was to evaluate the choroidal vascular response using optical coherence tomography (OCT) in patients with chronic central serous chorioretinopathy (CSCR) during transient increases in blood pressure. Methods: This observational, case–control study enrolled chronic CSCR patients and age-matched healthy controls. OCT scans of the macula were performed at rest and during hand-grip (HG) isometric exercise. Mean ocular perfusion pressure (MOPP) and subfoveal choroidal thickness (SCT) were measured at baseline and during stress. Quantitative OCT assessment included the bright area (BA, stroma), dark area (DA, vascular lumen), and total choroidal area (CA). The choroidal vascularity index (CVI) was calculated as DA/CA to assess vascular response to stress. A comparative analysis between CSCR patients and controls was conducted. Conclusions: MOPP was significantly higher (p = 0.008) at baseline in CSCR patients and further increased under stress compared to controls. SCT and CA were both significantly higher in CSCR patients than in healthy subjects at rest and under stress (p < 0.001), but no change occurred after HG. A significant decrease in CVI (p = 0.005) was noted in controls under stress, but not in CSCR patients. Additionally, a negative correlation between CVI and MOPP was found in healthy subjects (−0.648; p = 0.043). The study demonstrated a choroidal vasoconstrictive response to stress in healthy subjects, as evidenced by a decrease in CVI, but not in CSCR patients. This suggests that CSCR patients may experience impaired choroidal blood flow regulation, resulting in potentially higher perfusion pressures during stress without compensatory vasoconstriction, potentially affecting the choriocapillaris.


  • Posterior Uveitis

    by Piergiorgio Neri, Ilir Arapi, Uwe Pleyer, Moncef Khairallah, Soumyava Basu, Michele Nicolai, Vittorio Pirani, Alfonso Giovannini, Cesare Mariotti

    • 4 March 2013
      • Vol. 31  (3) , 458-62

    Long-term control of non-infectious paediatric panuveitis refractory to traditional immunesuppressive therapy, successfully treated with Adalimumab (HumiraTM).

    by Piergiorgio Neri, Chiara Eandi, Ilir Arapi, Chiara Posarelli, Cesare Mariotti, Alfonso Giovannini

    The aim of this paper is to present two cases of severe idiopathic non-infectious paediatric panuveitis, unresponsive to traditional therapy, successfully treated with Adalimumab (HumiraTM, Abbott Pharmaceutical Inc.) in the long term. The data of the two cases are presented and the literature is reviewed. At base line, case 1 had 0.2 in the RE and 0.5 in the LE, while case 2 had 0.5 and 0.4 in the RE and LE, respectively. The anterior chamber (AC) of case 1 had 3+ cells and 3+ flare in both eyes, as well as diffuse keratic precipitates (Kps). Case 2 presented 2+ cells and 3+ flare in both eyes, as well as tiny Kps in the inferior part of the endothelium. The Binocular Indirect Ophthalmoscopy (BIO) score was +2 in both eyes of case 1 and case 2 at first examination. After Adalimumab initiation, both patients presented a dramatic resolution of the ocular inflammation, as well as a rapid improvement of the BCVA. Case 1 had 0.8 and 1.0 in the RE and the LE, respectively, while case 2 presented 1.0 in both eyes. At the last visit, both patients presented a quiet uveitis and stable BCVA: case 1 had 0.8 and 1.0 in the RE and the LE, respectively, while case 2 presented 1.0 in both eyes. No side effects were recorded during this time. Adalimumab can be a promising drug for the therapy of severe, refractory paediatric uveitis, although further studies are needed on its application in uveitis.